JP2023528755A5 - - Google Patents

Info

Publication number
JP2023528755A5
JP2023528755A5 JP2022569071A JP2022569071A JP2023528755A5 JP 2023528755 A5 JP2023528755 A5 JP 2023528755A5 JP 2022569071 A JP2022569071 A JP 2022569071A JP 2022569071 A JP2022569071 A JP 2022569071A JP 2023528755 A5 JP2023528755 A5 JP 2023528755A5
Authority
JP
Japan
Prior art keywords
sequence
seq
nucleic acid
oligomer compound
equal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022569071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528755A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/036873 external-priority patent/WO2021252799A2/en
Publication of JP2023528755A publication Critical patent/JP2023528755A/ja
Publication of JP2023528755A5 publication Critical patent/JP2023528755A5/ja
Pending legal-status Critical Current

Links

JP2022569071A 2020-06-11 2021-06-10 Ｍｓｈ３の発現を低減するための化合物及び方法 Pending JP2023528755A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063038024P 2020-06-11 2020-06-11
US63/038,024 2020-06-11
US202063045728P 2020-06-29 2020-06-29
US63/045,728 2020-06-29
US202163178203P 2021-04-22 2021-04-22
US63/178,203 2021-04-22
PCT/US2021/036873 WO2021252799A2 (en) 2020-06-11 2021-06-10 Compounds and methods for reducing msh3 expression

Publications (2)

Publication Number Publication Date
JP2023528755A JP2023528755A (ja) 2023-07-06
JP2023528755A5 true JP2023528755A5 (https=) 2024-06-17

Family

ID=78846536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569071A Pending JP2023528755A (ja) 2020-06-11 2021-06-10 Ｍｓｈ３の発現を低減するための化合物及び方法

Country Status (4)

Country Link
US (1) US20230235331A1 (https=)
EP (1) EP4164656A4 (https=)
JP (1) JP2023528755A (https=)
WO (1) WO2021252799A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230313185A1 (en) * 2020-05-08 2023-10-05 Triplet Therapeutics, Inc. Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity
CN119173632A (zh) * 2022-05-10 2024-12-20 豪夫迈·罗氏有限公司 靶向cfp-elk1基因间区域的反义寡核苷酸

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
EP2462937A1 (en) * 2005-05-24 2012-06-13 Isis Pharmaceuticals, Inc. Modulation of LMW-PTPase Expression
WO2015051283A1 (en) * 2013-10-04 2015-04-09 Rana Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2015171918A2 (en) * 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
US10633410B2 (en) * 2014-12-22 2020-04-28 University Of Iowa Research Foundation Nucleic acid aptamers to treat histone-induced disease states
AU2016344609B2 (en) * 2015-10-28 2022-05-12 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of duchenne muscular dystrophy
JP7714162B6 (ja) * 2018-12-03 2025-09-08 タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法
US20210355491A1 (en) * 2020-04-20 2021-11-18 University Of Massachusetts Oligonucleotides for msh3 modulation
US20230313185A1 (en) * 2020-05-08 2023-10-05 Triplet Therapeutics, Inc. Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity

Similar Documents

Publication Publication Date Title
JP2022518929A5 (https=)
JP2024539596A5 (https=)
US6372427B1 (en) Cooperative oligonucleotides
AU2016202220B2 (en) Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
Gee et al. Assessment of high-affinity hybridization, RNase H cleavage, and covalent linkage in translation arrest by antisense oligonucleotides
JP2021530204A5 (https=)
JP2023536472A5 (https=)
JPH09510714A (ja) オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性
JPH09506770A (ja) ｃ−ｅｒｂＢの発現が関与する疾患を予防及び治療するためのアンチセンス核酸
JP2021526823A5 (https=)
JP2022520986A5 (https=)
JP2022509625A5 (https=)
JP2022527105A5 (https=)
JP2023536994A5 (https=)
JP2023528755A5 (https=)
CN118048356A (zh) 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
CN104321334A (zh) 三环核苷及由其制备的低聚化合物
JP2024523363A5 (https=)
JP2022515140A5 (https=)
JP2023543215A5 (https=)
TW202102676A (zh) 調節atxn2表現之寡核苷酸
JP2024522147A5 (https=)
TW202329983A (zh) Ｒｎａ編輯
JP2023549563A5 (https=)
TW202600821A (zh) 用於剪接調節ｕｎｃ１３ａ之組成物及方法